SCIENCE

SNS812

Indications

Pan-COVID

Mechanism of Action

SNS812 belong to a class of nucleic acid medicines called siRNA that uses a gene silencing mechanism (RNA interference, RNAi) to specifically cleave a highly conserved region of SARS-CoV-2 genome and thereby, inhibiting virus replication, and eliminating viruses in cells.

Current Status
  1. In vitro and in vivo preclinical pharmacological studies have been completed, including inhibition of Vero E6 cells and human ACE2 transgenic mice infection, cytotoxicity studies, off-target genes analysis and multi-species (mouse, rat, monkey) toxicological studies . The study results suggest that SNS812 is a candidate for anti- SARS-CoV-2 infection with low toxicity, off-target rate and immunogenicity
  2. An IND application was submitted to the US FDA for a phase I clinical trial of SNS812 on Aug 23, 2022; SNS812 has been greenlighted to proceed with phase 1 clinical trial  by the US FDA on Sep 22, 2022
Product advantages

Vaccines and antibodies currently on the market target the most mutated viral spike protein, which is easily escaped by the virus, leading to vaccine breakthroughs and repeated outbreaks of epidemics. SNS812 targets highly-conserved regions of the virus, and is expected to solve the problems of SARS-CoV-2 variants.

Market Potentials

According to the statistics of market analysis agencies, the COVID-19 preventive and therapeutic drug market is 150 billion (IQVIA Holdings) and 25.6 billion US dollars (IncInsightAce Analytic) respectively. SNS812 is currently one of the few drug candidates in the world that can target broad-spectrum of SARS-COV-2 variants.

R&D Progress
Complete
In Progress
Research Code Therapeutic Area Indication Pre-Clinical Phase I Phase II Phase III NDA Market More
  • SNS812
    Infection
    Pan-COVID

    SNS812 is a first-in-class siRNA new drug for COVID-19 infection. It specifically targets the highly conserved region of SARS-COV-2 genome to inhibit virus replication and eliminate viruses in cells.           

關閉

建議您使用以下瀏覽器觀看合一網站,
以獲得最佳瀏覽效果。

要下載瀏覽器,請直接點擊以下: IE瀏覽器現已不支援大多數網站,並將於2022年6月終止服務

如何使用IE找到Microsoft Edge?

  1. 開啟新分頁(紅色框)
    開啟新分頁
  2. 於搜尋框中打入Edge(紅色框),並按搜尋(藍色框)
    於搜尋框中打入Edge,並按搜尋
  3. 點擊【立即啟動】(藍框處)打開 Microsoft Edge
    啟動Microsoft Edge